Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
Adaptive Biotechnologies Corporation 2026 Q3 - Results - Earnings Call Presentation
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
Loading...